David M Mannino1, Dennis E Doherty, A Sonia Buist. 1. Division of Pulmonary and Critical Care Medicine, University of Kentucky Medicial Center, 800 Rose Street, MN 614, Lexington, KY 40536, USA. dmannino@uky.edu
Abstract
OBJECTIVE: To determine whether a modified Global Initiative on Obstructive Lung Diseases (GOLD) classification of chronic obstructive pulmonary disease (COPD) predicts mortality in a cohort of subjects followed for up to 11 years. METHODS: We analyzed data from 15,759 adult participants, aged 43-66 years at baseline, in the Atherosclerosis Risk in Communities (ARIC) study. All baseline and follow-up data were available for 15,440 (97.9%) of the initial participants. We classified subjects using a modification of the GOLD criteria for COPD (prebronchodilator forced expiratory volume in 1s (FEV(1)) stratification of disease severity), and added a "restricted" category (FEV(1)/FVC>70% and FVC<80% predicted). We used Cox proportional hazard models to determine the risk of impaired lung function on subsequent mortality, after adjusting for age, race, sex and smoking status. RESULTS: 1242 (8.0%) subjects died by the end of 1997. The overall rate of death was 8.9 per 1000 person years, but varied from 5.4/1000 among normal subjects to 42.9/1000 among subjects with GOLD Stage 3 or 4 COPD. After adjusting for covariates, all GOLD categories, along with the restricted category, predicted a higher risk of death: GOLD Stage 3 or 4, hazard ratio (HR) 5.7, 95% confidence interval (CI) 4.4, 7.3; GOLD Stage 2 HR 2.4, 95% CI 2.0, 2.9; GOLD Stage 1 HR 1.4, 95% CI 1.1, 1.6; GOLD Stage 0 HR 1.5, 95% CI 1.3, 1.8; and restricted HR 2.3, 95% CI 1.9, 2.8. CONCLUSION: The modified GOLD classification system of COPD predicts mortality in this cohort of middle-aged Americans followed for up to 11 years.
OBJECTIVE: To determine whether a modified Global Initiative on Obstructive Lung Diseases (GOLD) classification of chronic obstructive pulmonary disease (COPD) predicts mortality in a cohort of subjects followed for up to 11 years. METHODS: We analyzed data from 15,759 adult participants, aged 43-66 years at baseline, in the Atherosclerosis Risk in Communities (ARIC) study. All baseline and follow-up data were available for 15,440 (97.9%) of the initial participants. We classified subjects using a modification of the GOLD criteria for COPD (prebronchodilator forced expiratory volume in 1s (FEV(1)) stratification of disease severity), and added a "restricted" category (FEV(1)/FVC>70% and FVC<80% predicted). We used Cox proportional hazard models to determine the risk of impaired lung function on subsequent mortality, after adjusting for age, race, sex and smoking status. RESULTS: 1242 (8.0%) subjects died by the end of 1997. The overall rate of death was 8.9 per 1000 person years, but varied from 5.4/1000 among normal subjects to 42.9/1000 among subjects with GOLD Stage 3 or 4 COPD. After adjusting for covariates, all GOLD categories, along with the restricted category, predicted a higher risk of death: GOLD Stage 3 or 4, hazard ratio (HR) 5.7, 95% confidence interval (CI) 4.4, 7.3; GOLD Stage 2 HR 2.4, 95% CI 2.0, 2.9; GOLD Stage 1 HR 1.4, 95% CI 1.1, 1.6; GOLD Stage 0 HR 1.5, 95% CI 1.3, 1.8; and restricted HR 2.3, 95% CI 1.9, 2.8. CONCLUSION: The modified GOLD classification system of COPD predicts mortality in this cohort of middle-aged Americans followed for up to 11 years.
Authors: Kum Ju Chae; Gong Yong Jin; Young Min Han; Yong Seek Kim; Su Bin Chon; Young Sun Lee; Keun Sang Kwon; Hye Mi Choi; David Lynch Journal: Eur Radiol Date: 2015-02-14 Impact factor: 5.315
Authors: Leonardo M Fabbri; Cynthia Boyd; Piera Boschetto; Klaus F Rabe; A Sonia Buist; Barbara Yawn; Bruce Leff; David M Kent; Holger J Schünemann Journal: Proc Am Thorac Soc Date: 2012-12
Authors: Stefano Guerra; Duane L Sherrill; Claire Venker; Christina M Ceccato; Marilyn Halonen; Fernando D Martinez Journal: Thorax Date: 2010-06 Impact factor: 9.139
Authors: Y Kubota; S J London; M Cushman; A M Chamberlain; W D Rosamond; S R Heckbert; N Zakai; A R Folsom Journal: J Thromb Haemost Date: 2016-11-08 Impact factor: 5.824
Authors: R Perez-Padilla; W M Vollmer; J C Vázquez-García; P L Enright; A M B Menezes; A S Buist Journal: Int J Tuberc Lung Dis Date: 2009-03 Impact factor: 2.373